Novavax, Inc. – NASDAQ:NVAX
Novavax stock price today
$9.473
+1.19
+14.4%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Novavax stock price monthly change
-36.84%
month
Novavax stock price quarterly change
-36.84%
quarter
Novavax stock price yearly change
+67.61%
year
Novavax key metrics
Market Cap | 1.37B |
Enterprise value | N/A |
P/E | -1.14 |
EV/Sales | -0.04 |
EV/EBITDA | 0.13 |
Price/Sales | 0.42 |
Price/Book | -1.11 |
PEG ratio | -0.01 |
EPS | -3.1 |
Revenue | 831.68M |
EBITDA | -345.59M |
Income | -398.70M |
Revenue Q/Q | 15.94% |
Revenue Y/Y | -35.49% |
Profit margin | -39.43% |
Oper. margin | -38.64% |
Gross margin | 45.9% |
EBIT margin | -38.64% |
EBITDA margin | -41.55% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNovavax stock price history
Novavax stock forecast
Novavax financial statements
Average Price Target
$20.33
Potential upside: 114.65%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 424.42M | 58.00M | 13.67% |
|---|---|---|---|
| Sep 2023 | 22.06M | -130.77M | -592.71% |
| Dec 2023 | 291.34M | -178.38M | -61.23% |
| Mar 2024 | 93.85M | -147.55M | -157.21% |
| Jun 2023 | 1685048000 | 2.43B | 144.78% |
|---|---|---|---|
| Sep 2023 | 1657157000 | 2.33B | 140.93% |
| Dec 2023 | 1855342000 | 2.57B | 138.64% |
| Mar 2024 | 1353534000 | 2.22B | 164.06% |
| Jun 2023 | -171.93M | -7.77M | 61.33M |
|---|---|---|---|
| Sep 2023 | -39.65M | -18.39M | 197.12M |
| Dec 2023 | -176.78M | -9.07M | 100.38M |
| Mar 2024 | -83.55M | -7.25M | 5.88M |
Novavax alternative data
Covid-19 Vaccine
| 26 Feb 2023 | 31 | 0 | 0 | 0 |
|---|---|---|---|---|
| 5 Mar 2023 | 17 | 0 | 0 | 0 |
| 12 Mar 2023 | 18 | 0 | 0 | 0 |
| 19 Mar 2023 | 7 | 0 | 0 | 0 |
| 26 Mar 2023 | 10 | 0 | 0 | 0 |
| 2 Apr 2023 | 8 | 0 | 0 | 0 |
| 9 Apr 2023 | 8 | 0 | 0 | 0 |
| 16 Apr 2023 | 0 | 0 | 0 | 0 |
| 23 Apr 2023 | 12 | 0 | 0 | 0 |
| 30 Apr 2023 | 8 | 0 | 0 | 0 |
| 7 May 2023 | 0 | 0 | 0 | 0 |
| 14 May 2023 | 0 | 0 | 0 | 0 |
| 21 May 2023 | 10 | 0 | 0 | 0 |
| 28 May 2023 | 0 | 0 | 0 | 0 |
| 4 Jun 2023 | 11 | 0 | 0 | 0 |
| 11 Jun 2023 | 0 | 0 | 0 | 0 |
| 18 Jun 2023 | 9 | 0 | 0 | 0 |
| 25 Jun 2023 | 12 | 0 | 0 | 0 |
| 2 Jul 2023 | 13 | 0 | 0 | 0 |
| 9 Jul 2023 | 19 | 0 | 0 | 0 |
Novavax
| 26 Feb 2023 | 14 |
|---|---|
| 5 Mar 2023 | 12 |
| 12 Mar 2023 | 8 |
| 19 Mar 2023 | 8 |
| 26 Mar 2023 | 8 |
| 2 Apr 2023 | 5 |
| 9 Apr 2023 | 6 |
| 16 Apr 2023 | 6 |
| 23 Apr 2023 | 5 |
| 30 Apr 2023 | 4 |
| 7 May 2023 | 4 |
| 14 May 2023 | 4 |
| 21 May 2023 | 4 |
| 28 May 2023 | 4 |
| 4 Jun 2023 | 6 |
| 11 Jun 2023 | 6 |
| 18 Jun 2023 | 6 |
| 25 Jun 2023 | 9 |
| 2 Jul 2023 | 8 |
| 9 Jul 2023 | 8 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 45 |
|---|---|
| Sep 2023 | 59 |
| Oct 2023 | 54 |
| Nov 2023 | 43 |
| Dec 2023 | 5 |
| Jan 2024 | 6 |
| Feb 2024 | 4 |
| Apr 2024 | 14 |
| May 2024 | 28 |
| Jun 2024 | 15 |
| Jul 2024 | 16 |
| Dec 2024 | 4 |
| Aug 2023 | 1,992 |
|---|---|
| Sep 2023 | 1,992 |
| Oct 2023 | 1,992 |
| Nov 2023 | 1,992 |
| Dec 2023 | 1,992 |
| Jan 2024 | 1,992 |
| Feb 2024 | 1,992 |
| Apr 2024 | 1,543 |
| May 2024 | 1,543 |
| Jun 2024 | 1,543 |
| Jul 2024 | 1,543 |
Novavax other data
44.07%
-0.75%
of NVAX is owned by hedge funds
355
-58
32.78M
-714.59K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 47312 |
| Jun 2024 | 0 | 28904 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | CASEY MARK J officer: EVP, Chi.. | Common Stock | 41,900 | N/A | N/A | ||
Option | CASEY MARK J officer: EVP, Chi.. | Restricted Stock Units | 41,900 | N/A | N/A | ||
Option | TRIZZINO JOHN officer: EVP, CCO and CBO | Common Stock | 655 | N/A | N/A | ||
Option | TRIZZINO JOHN officer: EVP, CCO and CBO | Restricted Stock Units | 655 | N/A | N/A | ||
Option | KELLY JAMES PATRICK officer: EVP, CFO and Treasurer | Common Stock | 2,367 | $12.96 | $30,676 | ||
Option | KELLY JAMES PATRICK officer: EVP, CFO and Treasurer | Restricted Stock Units | 2,367 | N/A | N/A | ||
Sale | YOUNG JAMES F director | Common Stock | 7,500 | $14.09 | $105,675 | ||
Sale | YOUNG JAMES F director | Common Stock | 6,393 | $13.62 | $87,073 | ||
Sale | YOUNG JAMES F director | Common Stock | 1,107 | $14.28 | $15,808 | ||
Option | DUBOVSKY FILIP officer: President, R&D | Common Stock | 12,500 | $6.09 | $76,125 |
| Patent |
|---|
Application Filling date: 10 Aug 2021 Issue date: 7 Jul 2022 |
Grant Filling date: 21 Nov 2017 Issue date: 21 Jun 2022 |
Application Filling date: 25 Feb 2020 Issue date: 5 May 2022 |
Application Filling date: 10 Jan 2022 Issue date: 28 Apr 2022 |
Grant Filling date: 19 Mar 2019 Issue date: 22 Mar 2022 |
Application Filling date: 24 Nov 2021 Issue date: 17 Mar 2022 |
Grant Utility: Coronavirus vaccine formulations Filling date: 18 Mar 2021 Issue date: 22 Feb 2022 |
Grant Filling date: 20 Aug 2019 Issue date: 22 Feb 2022 |
Grant Filling date: 15 Mar 2018 Issue date: 21 Sep 2021 |
Application Filling date: 18 Mar 2021 Issue date: 29 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 10 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Stanley Charles Erck (1948) Pres, Chief Executive Officer & Director | $1,260,000 |
| Dr. Gregory M. Glenn (1954) Pres of R&D | $857,420 |
Mr. John Joseph Trizzino B.S., M.B.A. (1960) Executive Vice President and Chief Bus. & Commercial Officer | $676,830 |
| Mr. John A. Herrmann III (1966) Executive Vice President, Chief Legal Officer & Corporation Sec. | $655,950 |
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax: Sanofi Partnership Revitalizes My Magnum Opus
Moderna: Looking Beyond Covid, The Pipeline Is Promising
Novavax's COVID-19 Investment Thesis Is Old News
Novavax: The Short Squeeze Story Isn't A Complete No-Brainer
Novavax: Sell The Covid Rips
Novavax: Dead Cat Bounce
Novavax: The Dangerous Allure Of A Promising New Start
Moderna: Now's Your Chance (Rating Upgrade)
-
What's the price of Novavax stock today?
One share of Novavax stock can currently be purchased for approximately $9.47.
-
When is Novavax's next earnings date?
Unfortunately, Novavax's (NVAX) next earnings date is currently unknown.
-
Does Novavax pay dividends?
No, Novavax does not pay dividends.
-
How much money does Novavax make?
Novavax has a market capitalization of 1.37B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 38.48% to 983.71M US dollars.
-
What is Novavax's stock symbol?
Novavax, Inc. is traded on the NASDAQ under the ticker symbol "NVAX".
-
What is Novavax's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Novavax?
Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Novavax's key executives?
Novavax's management team includes the following people:
- Mr. Stanley Charles Erck Pres, Chief Executive Officer & Director(age: 77, pay: $1,260,000)
- Dr. Gregory M. Glenn Pres of R&D(age: 71, pay: $857,420)
- Mr. John Joseph Trizzino B.S., M.B.A. Executive Vice President and Chief Bus. & Commercial Officer(age: 65, pay: $676,830)
- Mr. John A. Herrmann III Executive Vice President, Chief Legal Officer & Corporation Sec.(age: 59, pay: $655,950)
-
How many employees does Novavax have?
As Jul 2024, Novavax employs 1,543 workers.
-
When Novavax went public?
Novavax, Inc. is publicly traded company for more then 29 years since IPO on 5 Dec 1995.
-
What is Novavax's official website?
The official website for Novavax is novavax.com.
-
Where are Novavax's headquarters?
Novavax is headquartered at 21 Firstfield Road, Gaithersburg, MD.
-
How can i contact Novavax?
Novavax's mailing address is 21 Firstfield Road, Gaithersburg, MD and company can be reached via phone at +240 2682000.
-
What is Novavax stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Novavax in the last 12 months, the avarage price target is $20.33. The average price target represents a 114.65% change from the last price of $9.47.
Novavax company profile:
Novavax, Inc.
novavax.comExchange:
NASDAQ
Full time employees:
1,543
Industry:
Biotechnology
Sector:
Healthcare
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
21 Firstfield Road
Gaithersburg, MD 20878
Gaithersburg, MD 20878
CIK: 0001000694
ISIN: US6700024010
CUSIP: 670002401
